These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370 [TBL] [Abstract][Full Text] [Related]
3. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
4. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cekic C; Day YJ; Sag D; Linden J Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469 [TBL] [Abstract][Full Text] [Related]
5. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772 [TBL] [Abstract][Full Text] [Related]
6. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
7. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Kerkar SP; Leonardi AJ; van Panhuys N; Zhang L; Yu Z; Crompton JG; Pan JH; Palmer DC; Morgan RA; Rosenberg SA; Restifo NP Mol Ther; 2013 Jul; 21(7):1369-77. PubMed ID: 23568260 [TBL] [Abstract][Full Text] [Related]
8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
14. IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses. Santana Carrero RM; Beceren-Braun F; Rivas SC; Hegde SM; Gangadharan A; Plote D; Pham G; Anthony SM; Schluns KS Proc Natl Acad Sci U S A; 2019 Jan; 116(2):599-608. PubMed ID: 30587590 [TBL] [Abstract][Full Text] [Related]
15. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. Schüler T; Blankenstein T J Immunol; 2003 May; 170(9):4427-31. PubMed ID: 12707316 [TBL] [Abstract][Full Text] [Related]
16. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840 [TBL] [Abstract][Full Text] [Related]
17. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. Kimura T; Sugaya M; Oka T; Blauvelt A; Okochi H; Sato S Oncotarget; 2015 Jul; 6(20):18081-93. PubMed ID: 26098776 [TBL] [Abstract][Full Text] [Related]
18. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401 [TBL] [Abstract][Full Text] [Related]
19. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754 [TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]